A pilot study of rituximab in patients with recurrent, classic Hodgkin disease.

@article{Younes2003APS,
  title={A pilot study of rituximab in patients with recurrent, classic Hodgkin disease.},
  author={Anas Younes and Jorge E Romaguera and Frederick Hagemeister and Peter Mclaughlin and Maria Alma Rodriguez and Paolo Fabio Fiumara and Andre Goy and Sima Jeha and John T. Manning and Dan B. Jones and Lynne V. Abruzzo and L Jeffrey Medeiros},
  journal={Cancer},
  year={2003},
  volume={98 2},
  pages={310-4}
}
BACKGROUND To explore the potential role of infiltrating benign B cells in classic Hodgkin disease (HD) lesions in supporting the survival of malignant Hodgkin and Reed-Sternberg (H/RS) cells, the authors initiated a pilot study of rituximab. Rituximab is used to primarily deplete normal B cells from HD lesions. METHODS Patients with recurrent, classic HD who had received a minimum of two prior treatment regimens, regardless of whether H/RS cells expressed CD20, were treated with 6 weekly… CONTINUE READING
58 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 58 extracted citations

Similar Papers

Loading similar papers…